EP1230360A4
(en)
*
|
1999-11-09 |
2003-04-02 |
Human Genome Sciences Inc |
15 human secreted proteins
|
CA2392477A1
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
CA2412377A1
(en)
|
2000-06-06 |
2001-12-13 |
Bristol-Myers Squibb Company |
B7-related nucleic acids and polypeptides and their uses for immunomodulation
|
EA007275B1
(en)
*
|
2001-05-24 |
2006-08-25 |
Займодженетикс, Инк. |
Taci-immunoglobulin fusion proteins
|
CN104436190A
(en)
|
2005-06-08 |
2015-03-25 |
达纳-法伯癌症研究院公司 |
Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
|
EP1976567B1
(en)
|
2005-12-28 |
2020-05-13 |
The Scripps Research Institute |
Natural antisense and non-coding rna transcripts as drug targets
|
MX2011005691A
(en)
|
2008-11-28 |
2011-07-20 |
Univ Emory |
Methods for the treatment of infections and tumors.
|
JP6091752B2
(en)
|
2008-12-04 |
2017-03-08 |
クルナ・インコーポレーテッド |
Treatment of erythropoietin (EPO) -related diseases by suppression of natural antisense transcripts against EPO
|
CN107338251A
(en)
|
2008-12-04 |
2017-11-10 |
库尔纳公司 |
It is diseases related that natural antisense transcript by suppressing tumor suppressor gene treats tumor suppressor gene
|
EP2370581B1
(en)
|
2008-12-04 |
2016-08-03 |
CuRNA, Inc. |
Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
|
UA109108C2
(en)
|
2008-12-09 |
2015-07-27 |
Дженентек, Інк. |
Anti-pd-ll antibody and its use to enhance t-cell function
|
EP2396408B1
(en)
*
|
2009-02-12 |
2017-09-20 |
CuRNA, Inc. |
Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
|
HUE026280T2
(en)
|
2009-02-12 |
2016-06-28 |
Curna Inc |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
JP6116242B2
(en)
|
2009-03-16 |
2017-04-19 |
クルナ・インコーポレーテッド |
Treatment of NRF2-related diseases by suppression of natural antisense transcripts against nuclear factor (erythrocyte-derived 2) -like 2 (NRF2)
|
JP5904935B2
(en)
|
2009-03-17 |
2016-04-20 |
クルナ・インコーポレーテッド |
Treatment of DLK1-related diseases by suppression of natural antisense transcripts against Delta-like 1 homolog (DLK1)
|
CN103223177B
(en)
|
2009-05-06 |
2016-08-10 |
库尔纳公司 |
By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene
|
WO2010129746A2
(en)
|
2009-05-06 |
2010-11-11 |
Curna, Inc. |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
CA3185821A1
(en)
|
2009-05-08 |
2010-11-11 |
Curna, Inc. |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
|
EP2432881B1
(en)
|
2009-05-18 |
2017-11-15 |
CuRNA, Inc. |
Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
|
KR101703695B1
(en)
|
2009-05-22 |
2017-02-08 |
큐알엔에이, 인크. |
Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
|
KR20120024819A
(en)
|
2009-05-28 |
2012-03-14 |
오피케이오 큐알엔에이, 엘엘씨 |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
ES2620960T3
(en)
|
2009-06-16 |
2017-06-30 |
Curna, Inc. |
Treatment of diseases related to a collagen gene by inhibiting a natural antisense transcript to a collagen gene
|
KR101702689B1
(en)
|
2009-06-16 |
2017-02-06 |
큐알엔에이, 인크. |
Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
|
CA2765889A1
(en)
|
2009-06-24 |
2010-12-29 |
Opko Curna, Llc |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
KR101807324B1
(en)
|
2009-06-26 |
2017-12-08 |
큐알엔에이, 인크. |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
US20120252869A1
(en)
|
2009-07-24 |
2012-10-04 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
ES2585360T3
(en)
|
2009-08-05 |
2016-10-05 |
Curna, Inc. |
Treatment of diseases related to an insulin gene (INS) by inhibition of natural antisense transcription in an insulin gene (INS)
|
KR101827015B1
(en)
|
2009-08-11 |
2018-02-07 |
큐알엔에이, 인크. |
Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
|
CN102482670B
(en)
|
2009-08-21 |
2018-06-15 |
库尔纳公司 |
CHIP relevant diseases are treated by inhibiting the natural antisense transcript of ' C-terminal of HSP70- interaction proteins ' (CHIP)
|
WO2011031482A2
(en)
|
2009-08-25 |
2011-03-17 |
Curna, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
US20120295952A1
(en)
|
2009-09-25 |
2012-11-22 |
Curna, Inc. |
Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
|
JP6025567B2
(en)
|
2009-12-16 |
2016-11-16 |
カッパーアールエヌエー,インコーポレイテッド |
Treatment of MBTPS1-related diseases by inhibition of the natural antisense transcript against the membrane-bound transcription factor peptidase, site 1 (MBTPS1)
|
RU2619185C2
(en)
|
2009-12-23 |
2017-05-12 |
Курна, Инк. |
Treatment of diseases associated with uncoupling proteins 2 (ucp2), by inhibiting of natural antisense transcript to ucp2
|
WO2011079261A2
(en)
|
2009-12-23 |
2011-06-30 |
Curna, Inc. |
Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
|
JP5982288B2
(en)
|
2009-12-29 |
2016-08-31 |
カッパーアールエヌエー,インコーポレイテッド |
Treatment of tumor protein 63-related diseases by inhibition of natural antisense transcripts against tumor protein 63 (p63)
|
CA2785173A1
(en)
|
2009-12-29 |
2011-07-28 |
Curna, Inc. |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
ES2677044T3
(en)
|
2009-12-31 |
2018-07-27 |
Curna, Inc. |
Treatment of diseases related to insulin receptor substrate 2 (IRS2) by inhibition of natural antisense transcript for IRS2 and transcription factor E3 (TFE3)
|
NO2521784T3
(en)
|
2010-01-04 |
2018-05-05 |
|
|
RU2612161C2
(en)
|
2010-01-06 |
2017-03-02 |
Курна, Инк. |
Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to pancreatic developmental gene
|
ES2664866T3
(en)
|
2010-01-11 |
2018-04-23 |
Curna, Inc. |
Treatment of diseases related to sex hormone binding globulin (shbg) by inhibition of the natural antisense transcript to shbg
|
CN102782135A
(en)
|
2010-01-25 |
2012-11-14 |
库尔纳公司 |
Treatment of RNase H1 related diseases by inhibition of natural antisense transcript to RNase H1
|
KR101838308B1
(en)
|
2010-02-22 |
2018-03-13 |
큐알엔에이, 인크. |
Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
|
CA2795145C
(en)
|
2010-04-02 |
2019-01-22 |
Curna, Inc. |
Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
|
EP3517613A1
(en)
|
2010-04-09 |
2019-07-31 |
CuRNA, Inc. |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
US9089588B2
(en)
|
2010-05-03 |
2015-07-28 |
Curna, Inc. |
Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT)
|
TWI586356B
(en)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
|
EP2576784B1
(en)
|
2010-05-26 |
2017-11-15 |
CuRNA, Inc. |
Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
|
EP2576783B1
(en)
|
2010-05-26 |
2017-11-29 |
CuRNA, Inc. |
Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
|
PT2585596T
(en)
|
2010-06-23 |
2021-03-23 |
Curna Inc |
Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
|
NO2593547T3
(en)
|
2010-07-14 |
2018-04-14 |
|
|
WO2012047956A2
(en)
|
2010-10-06 |
2012-04-12 |
Opko Curna Llc |
Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
|
CN103180445B
(en)
|
2010-10-22 |
2018-02-16 |
库尔纳公司 |
IDUA relevant diseases are treated by suppressing the natural antisense transcript of α L iduronases (IDUA)
|
US10000752B2
(en)
|
2010-11-18 |
2018-06-19 |
Curna, Inc. |
Antagonat compositions and methods of use
|
JP6071893B2
(en)
|
2010-11-23 |
2017-02-01 |
カッパーアールエヌエー,インコーポレイテッド |
Treatment of NANOG-related diseases by inhibition of natural antisense transcripts to NANOG
|
CN103620036B
(en)
|
2011-06-09 |
2016-12-21 |
库尔纳公司 |
FXN relevant disease is treated by the natural antisense transcript of suppression Frataxin (FXN)
|
CN108272782B
(en)
|
2011-09-06 |
2021-04-23 |
库尔纳公司 |
Use of small molecules in preparation of medicine for treating Dravet syndrome or generalized epilepsy with febrile convulsion adjunctive disease
|
ES2694592T3
(en)
|
2012-03-15 |
2018-12-21 |
Curna, Inc. |
Treatment of diseases related to brain-derived neurotrophic factor (BDNF) by inhibition of the natural antisense transcript of BDNF
|
JP6448533B2
(en)
|
2012-05-15 |
2019-01-09 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1 / PD-L1 signaling
|